Plasma Markers of Cholesterol Homeostasis and Apolipoprotein B‐100 Kinetics in the Metabolic Syndrome
Open Access
- 1 April 2003
- journal article
- Published by Wiley in Obesity Research
- Vol. 11 (4) , 591-596
- https://doi.org/10.1038/oby.2003.83
Abstract
Objective: The metabolic syndrome is characterized by defective hepatic apolipoprotein B‐100 (apoB) metabolism. Hepato‐intestinal cholesterol metabolism may contribute to this abnormality.Research Methods and Procedures: We examined the association of cholesterol absorption and synthesis with the kinetics of apoB in 35 obese subjects with the metabolic syndrome. Plasma ratios of campesterol and lathosterol to cholesterol were used to estimate cholesterol absorption and synthesis, respectively. Very‐low‐density lipoprotein (VLDL), intermediate‐density lipoprotein (IDL), and low‐density lipoprotein apoB kinetics were studied using stable isotopy and mass spectrometry. Kinetic parameters were derived using multicompartmental modeling.Results: Compared with controls, the obese subjects had significantly lower plasma ratios of campesterol, but higher plasma ratios of lathosterol (p < 0.05 in both). This was associated with elevated VLDL‐apoB secretion rate (p < 0.05) and delayed fractional catabolism of IDL and low‐density lipoprotein‐apoB (p < 0.01). In the obese group, plasma ratios of campesterol correlated inversely with VLDL‐apoB secretion (r = −0.359, p < 0.05), VLDL‐apoB (r = −0.513, p < 0.01) and IDL‐apoB (r = −0.511, p < 0.01) pool size, and plasma lathosterol ratio (r = −0.366, p < 0.05). Subjects with low cholesterol absorption had significantly higher VLDL‐apoB secretion, VLDL‐apoB and IDL‐apoB pool size, and plasma lathosterol ratio (p < 0.05 in both) than those with high cholesterol absorption.Discussion: Subjects with the metabolic syndrome have oversecretion of VLDL‐apoB and decreased catabolism of apoB‐containing particles and low absorption and high synthesis rates of cholesterol. These changes in cholesterol homeostasis may contribute to the kinetic defects in apoB metabolism in the metabolic syndrome.Keywords
This publication has 28 references indexed in Scilit:
- Body Weight Modulates Cholesterol Metabolism in Non‐Insulin Dependent Type 2 DiabeticsObesity Research, 2002
- Mechanism of Action of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor on Apolipoprotein B-100 Kinetics in Visceral ObesityJournal of Clinical Endocrinology & Metabolism, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Insulin resistance and cardiovascular diseaseJournal of Clinical Investigation, 2000
- Reduction in Visceral Adipose Tissue Is Associated with Improvement in Apolipoprotein B-100 Metabolism in Obese MenJournal of Clinical Endocrinology & Metabolism, 1999
- Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesityInternational Journal of Obesity, 1998
- Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDMDiabetologia, 1995
- Comparison of immunoturbidimetric and Lowry methods for measuring concentration of very low density lipoprotein apolipoprotein B-100 in plasma.Journal of Clinical Pathology, 1994
- In vivo stimulation of low-density lipoprotein degradation by insulinDiabetes, 1984
- Overproduction of low density lipoproteins associated with coronary heart disease.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1983